Pennsylvania Medicaid coverage for Zepbound (Weight Loss)

Effective January 1, 2026, drugs containing a GLP-1 receptor agonist are not covered for the treatment of overweight or obesity for MA beneficiaries. The policy states: 'GLP-1 Receptor Agonists are not covered for the treatment of overweight or obesity.'

Policy note: Pennsylvania MA explicitly ended coverage of all GLP-1 receptor agonists for overweight/obesity effective January 1, 2026. Class-wide exclusion applies to Zepbound for weight_loss indication.

Policy effective January 1, 2026 · verified June 4, 2026 · source: mab2025112403.pdf